Dr Ola Landgren at ASH 2014: Final results from NCI phase II pilot study of carfilzomib, lenalidomide and dexamethasone in high-risk smouldering myeloma

Dr Ola Landgren at ASH 2014: Final results from NCI phase II pilot study of carfilzomib, lenalidomide and dexamethasone in high-risk smouldering myeloma

EMJ

5 years
786 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Ola Landgren (Memorial Sloane Kettering Cancer Center, New York, NY) discusses the final results from the NCI phase II pilot study of carfilzomib, lenalidomide and dexamethasone in 12 patients with high-risk smouldering multiple myeloma. He assesses the risks and benefits of this therapeutic approach in clinical practice.
Up Next Autoplay